Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

BioXcel Therapeutics, Inc. (BTAIQ) vs Redhill Biopharma Ltd. (RDHL)

BioXcel Therapeutics, Inc. and Redhill Biopharma Ltd. are both Drug Manufacturers Specialty & Generic companies. Redhill Biopharma Ltd. is the larger, with a market value of $3.2M against $2.3M — 1.4× the size. BioXcel Therapeutics, Inc. grew revenue faster over the last twelve months: −14.5% against −61.9%. Redhill Biopharma Ltd. has the higher net margin (25.2% vs −9,549.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Redhill Biopharma Ltd. leads on 9 and BioXcel Therapeutics, Inc. on 6.

Valuation

Metric BTAIQ RDHL Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 1.63 0.32 2.25
P/B n/m n/m 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 228.73 0.30 2.56
Earnings yield (9,475.00%) (122,133.34%) (2.99%)
Free cash flow yield (4,201.65%) (909.75%) 0.00%

Profitability

Metric BTAIQ RDHL Drug Manufacturers Specialty & Generic median
Gross margin 53.10% 35.16% 53.94%
Operating margin (6,054.72%) 0.00% 0.00%
Net margin (9,549.87%) 25.20% 0.00%
Free cash flow margin (6,860.38%) 0.00% 0.00%
Return on equity 63.52% 0.00% (0.40%)
Return on assets (259.62%) 0.00% (3.32%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BTAIQ RDHL Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (14.52%) (61.93%) 10.01%
EPS growth (last fiscal year) 75.63% 97.91% —
Revenue growth, 5-year CAGR — (66.15%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BTAIQ RDHL Drug Manufacturers Specialty & Generic median
Debt to equity (0.90) 0.00 0.05
Current ratio 0.21 0.56 2.31
Net debt to EBITDA (1.61) 0.53 0.85

Dividend

Metric BTAIQ RDHL Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric BTAIQ RDHL Drug Manufacturers Specialty & Generic median
Market cap 2.31m 3.22m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack